Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05088759 · ClinicalTrials.gov registry record · NA
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management
A NA study of ASCVD and Hyperlipemia, Mixed, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT05088759: Active NA study of ASCVD and Hyperlipemia, Mixed, sponsored by Brigham and Women's Hospital.
NCT05088759 is a NA study of ASCVD and Hyperlipemia, Mixed that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 400 participants, below the 13,372-participant average among 5 other ASCVD trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05088759, a NA study of ASCVD and Hyperlipemia, Mixed, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values. The 400 patients will be comprised of 200 in the "Hospitalized Patient Cohort" and 200 in the "Outpatient Clinic Cohort." The allocation ratio will be 1:1 for an electronic alert-based CDS (EPIC BPA) notification versus no notification.
Primary Outcome
frequency of prescription of appropriate LDL-lowering therapy, including statin intensification or addition of ezetimibe or PCSK9 inhibitors at 90 days in hospitalized and clinic patients with ASCVD, including recent ACS, and a most recent (within 1 year) or current LDL-C value greater than 80 mg/dL who are on a statin.
Conditions Studied
Interventions
- BEHAVIORAL Alert
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What the registry record for NCT05088759 still lists
NCT05088759 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 13,372-participant average among 5 other ASCVD trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with ASCVD appearing as the primary indexed condition, and to 1 intervention - of which Alert is the first listed.
NCT05088759 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05088759 about?
NCT05088759 is a clinical study titled "Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management". A 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) based on LDL-C values. The 400 patients will be comprised of 200 in the "Hospitalized Patient ...
What is the current status of trial NCT05088759?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2021-10-08. Estimated completion is 2026-06-30.
What conditions does trial NCT05088759 study?
This clinical trial studies the following conditions: ASCVD, Hyperlipemia, Mixed.
What interventions are being tested in trial NCT05088759?
The interventions under investigation include: Alert (BEHAVIORAL).
Who is sponsoring clinical trial NCT05088759?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05088759 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ASCVD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
RECRUITING · NA
-
Notification of Incidental Coronary Artery Calcium in Patients With Atherosclerotic Cardiovascular Disease (NOTIFY-ASCVD)
ACTIVE NOT RECRUITING · NA
-
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
RECRUITING · Phase 4
-
ACHIEVE Pilot Statins for Vascular Protection
ACTIVE NOT RECRUITING
-
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI